LONDON (Reuters) – European regulators have for the first time recommended approval of a copycat insulin for diabetics, posing a threat to French drugmaker Sanofi whose top-selling Lantus is now set to face a cheaper rival in 2015.
The new drug, known as Abasria, is made by U.S. rival Eli Lilly, which has developed it as a so-called biosimilar version of Sanofi’s $8 billion-a-year Lantus, or insulin glargine.
LONDON, June 26 (Reuters) – A vote by U.S. experts against
accelerated approval of a new ovarian cancer drug from
AstraZeneca has dented its claims of research prowess,
which were used to see off a $118 billion bid from Pfizer
In itself, the setback will have little impact on earnings
prospects – but it coincides with heightened scrutiny of the
British drugmaker’s research and development (R&D) machine and
continued talk that Pfizer may return if it stumbles.
LONDON (Reuters) – U.S. drugmaker AbbVie set out the strategic rationale for acquiring Shire on Wednesday as a battle for control of the London-listed company, which has spurned AbbVie’s $46 billion bid, entered a new phase.
AbbVie called for talks and said it was willing to move quickly and cooperatively to clinch a deal, arguing it would create more value from Shire’s assets than the hyperactivity and rare diseases specialist could do on its own.
LONDON (Reuters) – Shire (SHP.L: Quote, Profile, Research, Stock Buzz), which has spurned a $46 billion takeover offer from U.S. group AbbVie (ABBV.N: Quote, Profile, Research, Stock Buzz) as inadequate, has a new reason to argue it is worth more after a U.S. court backed patent claims on its top-selling drug Vyvanse.
The summary judgment in Shire’s favor, handed down by the U.S. District Court for the District of New Jersey, blocks five generic drug manufacturers from launching cheap copies of the hyperactivity drug before 2023, unless they win the case on appeal.
LONDON, June 23 (Reuters) – Shire flagged the
promise of existing and new drugs on Monday as evidence that
AbbVie’s $46 billion offer undervalued the company, the
latest British firm to be targeted by a U.S. group seeking lower
Shire is taking a leaf out of AstraZeneca’s playbook
by disclosing long-range internal forecasts – a tactic used
successfully by its larger London-listed rival in fending off a
$118 billion bid from Pfizer.